



Correction to: Leucine-Rich Alpha-2-Glycoprotein as a non-invasive biomarker for pediatric acute appendicitis: a systematic review and meta-analysis

Javier Arredondo Montero^{1,2} · Blanca Paola Pérez Riveros² · Oscar Emilio Bueso Asfura² · María Rico Jiménez² · Natalia López-Andrés³ · Nerea Martín-Calvo^{2,4,5}

Published online: 2 June 2023
© The Author(s) 2023

Correction to: European Journal of Pediatrics

<https://doi.org/10.1007/s00431-023-04978-2>

In the original published version of the above article there were two typographical errors.

1. The text originally says "A standardization of metrics was performed before the quantitative analysis. The random-effect meta-analysis of those studies included **104** cases of PAA and 174 controls (Fig. 3)". However the correct number should have been **103** cases, not 104 (check Fig. 3)

2. On Table 3, on the Kakar et al. (2021) study, for Urinary LRG1 AA (µg/mL), the superindex (CAA) appears as a number and not as a letter. It should have been a "d", not a "4", since the legend of the table does not include numbers. The Table 3 has been corrected as follows.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s00431-023-04978-2>.

✉ Javier Arredondo Montero
jarredondom@alumni.unav.es;
Javier.montero.arredondo@gmail.com

¹ Department of Pediatric Surgery, Hospital Universitario de Navarra, 31008 Pamplona, Navarra, Spain

² Department of Preventive Medicine and Public Health, School of Medicine, University of Navarra, Pamplona, Spain

³ Cardiovascular Translational Research. NavarraBiomed (Miguel Servet Foundation), Hospital Universitario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain

⁴ IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

⁵ CIBER de Fisiopatología de la Obesidad y la Nutrición, Instituto de Salud Carlos III, Madrid, Spain

Table 3 Urinary Leucine-Rich Alpha-2 Glycoprotein summary of publications included in this review

Author	Study design	Age (Range)	Sex (M/F)	Total N	N in AA	N in CG	Urinary LRG1 AA (µg/mL)	Urinary LRG1 CG (µg/mL)	P (CG vs AA)	P (NCAA vs CAA)	Cutoff µg/mL (CG vs AA)	AUC (AA vs control) (95% CI)	Se (%)	Sp (%)
Kentis et al. (2010) [10]	Prospective	-	31/36	67	25 (CAA:4)	42	-	-	-	-	-	0.97 (0.93–1)**	-	-
Kentis et al. (2012) [11]	Prospective	-	26/23	49	24 (NCAA: 18 CAA: 6)	25	3.9 (0.9–19.3) ^b (interference adjusted)	0.3 (0.1–0.8) ^b (interference adjusted)	-	-	-	0.80 (0.67–0.92)* 0.98 (0.96–1)**	-	-
Kharbanda et al. (2012) [12]	Prospective	3–18	92/84	176	58 (NCAA: 43 CAA: 15)	118	683.5 (122.3–3832.3) ^{b***} (UA) [NCAA: 252.7 (106.7–2547.5) ^{b***} (UA) CAA: 20576.8 (1750.4–38544.3) ^{b***} (UA)] 0.68 (0.12–3.83)^{b***}(UA) 1.54 (2.82)^d(UA)	225.2 (46.5–1442.8) ^{b***} (UA) 0.23 (0.05–1.44)^{b***}(UA) 0.57 (1.04)^e(UA)	0.008 ^(UA)	<0.001 ^(UA)	42 ^{***} (UA) 0.04 ^{***} (UA)	0.63 (0.52–0.73) ^(UA)	100	23
Saló et al. (2016) [13]	Prospective	3–14	27/17	44	22 (NCAA: 14 CAA: 8)	22	0.078 (0.03–16.78) ^{X,c} [NCAA: 0.06 (0.04–0.29) ^{X,c} 4.24 (4.38)^{X,c}	0.014 (0.005–0.16) ^{X,c} 0.05 (0.04)^{X,c}	<0.001 ^X	0.003 ^X	0.036 ^X 0.26 ^(UA)	0.86 (0.79–0.99) ^X 0.65 (0.48–0.81) ^(UA)	86 ^X 64 ^(UA)	73 ^X 50 ^(UA)
Yap et al. (2019) [14]	Prospective	4–16	81/67	148	42 (CAA: 9 NA: 5)	106	0.22 (0.0003–7.20) ^{X,c} 1.91 (1.65)^{X,c}	0.04 (0.0003–3.29) ^{X,c} 0.84 (0.65)^{X,c}	0.014 ^X	-	-	0.63 (0.53–0.72) ^X	-	-
Yap et al. (2020) [15]	Prospective	4–16	15/19	34	17 (NCAA: 9 CAA: 8)	17	0.17 (0.026–1.068) ^{X,b} 0.42 (0.84)^{X,d}	0.014 (0.002–0.353) ^{X,b} 0.12 (0.28)^{X,d}	0.031 ^X	-	1.5 ^X	0.72 (0.54–0.90) ^X	17.7 ^X	100 ^X
Mahalik et al. (2021) [16]	Prospective	3–16	31/10	41	20 (NCAA: 2 CAA: 5 NOM: 13)	21	8.57 (8.02) ^a (UA) 0.28 (0.40) ^X MU not provided	6.68 (7.85) ^a (UA) 0.22 (0.31) ^X MU not provided	0.456 ^(UA) 0.59 ^X	-	-	0.59 (0.41–0.77) not specified if adjusted or unadjusted	-	-

Table 3 (To be continued)

Author	Study design	Age (Range)	Sex M/F	Total N	N in AA	N in CG	Urinary LRG1 AA (µg/mL)	Urinary LRG1 CG (µg/mL)	P (CG vs AA)	P (NCAA vs CAA)	Cutoff µg/mL (CG vs AA)	AUC (AA vs control) (95% CI)	Se (%)	Sp (%)
Kakar et al. (2021) [17]	Prospective	7–17	89/64	153	97 (NCAA:45 CAA:52)	56	NCAA: 0.35 (0.05–1.38) ^{b(UA)} CAA: 0.1 (0.03–0.73) ^{b(UA)} NCAA: 0.59 (1.02) ^{d(UA)} CAA: 0.29 (0.53) ^{d(UA)}	0.04 (0.02–0.10) ^{2(UA)} 0.05 (0.06) ^{d(UA)}	<0.001 ^(UA)	-	0.175 ^(UA)	0.70 (0.62–0.79) ^(UA)	54.2	83.9

Bold numbers: standardized metrics and estimated mean (sd) from median (IQR/range) as calculated by authors

LRG1 Leucine-Rich Alpha-2 Glycoprotein, *AA* Acute appendicitis group, *CG* Control group, *NCAA* Non-complicated acute appendicitis, *CAA* Complicated acute appendicitis, *NS* non-statistically significant, *Se* sensitivity, *Sp* specificity, *UA* Unadjusted to dehydration through urine creatinine, *NA* Negative appendectomies, *MU* Measurement units, *NOM* non-operative management *ELISA; **High precision mass spectroscopy; ***ng/mL; ****Conversion to µg/mL from ng/mL X: adjusted to dehydration with urinary creatinine – LRG/Cr (g/mol) XX: adjusted to dehydration with urinary creatinine – units not provided

^aMean (standard deviation)

^bMedian (Interquartile range)

^cMedian (range)

^dMean (standard deviation) obtained from Median (IQR)

^eMean (standard deviation) obtained from median (Range)

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.